← Back

Poolbeg Pharma PLC

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.

Price · split & dividend adjusted
News & notes moving POLB.LSE
Critical Materials & Supply Chain

ACG Metals hits full-year oxide output target in six months

ACG Metals beat its full-year oxide production target in just six months, helped by a 64% jump in its realised gold price to $4,838 an ounce. First copper and zinc concentrate production is now expected in August. Rockfire Resources returned strong zinc and silver grades at its Molaoi project in Greece, with preliminary readings showing zinc values as high as 37.7%, and is fast-tracking feasibility studies and permit applications to reopen underground workings. Sunda Energy applied for a permit to explore an offshore area of New Zealand's Taranaki Basin covering around 645 square kilometres, triggering a three-month window for competing bids. CelLBxHealth remains on track for revenues of at least £2.1 million this year, up 50% on 2025, while searching for a new chief executive with no impact on trading expected. Poolbeg Pharma raised £3.5 million through a placing to fund two clinical trials and strengthen partnering discussions, extending its cash runway into the second quarter of 2028.
Yahoo Finance·44dRead more ▾